Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study ...

Get the latest Rhythm Pharmaceuticals, Inc. (RYTM) stock news and headlines to help you in your trading and investing decisions.

Rhythm Pharmaceuticals, Inc. (RYTM) shares rallied 36.6% in the last trading session to close at $89. This move can be attributable to notable volume with a higher number of shares being traded than ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

We just received data on a new analyst forecast for $RYTM. Joseph Stringer from Needham set a price target of 95.0 for RYTM.

Conceived by industrial designer Jorge Paez, the sleek new RYTM turntable marries modern, minimalist aesthetics with the latest tech.

Rhythm Pharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest RYTM financial statements, income statements and financial ratios.

Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R ...